These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11414591)

  • 1. Latent class modeling approaches for assessing diagnostic error without a gold standard: with applications to p53 immunohistochemical assays in bladder tumors.
    Albert PS; McShane LM; Shih JH;
    Biometrics; 2001 Jun; 57(2):610-9. PubMed ID: 11414591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network.
    McShane LM; Aamodt R; Cordon-Cardo C; Cote R; Faraggi D; Fradet Y; Grossman HB; Peng A; Taube SE; Waldman FM
    Clin Cancer Res; 2000 May; 6(5):1854-64. PubMed ID: 10815908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 immunohistochemistry in bladder cancer--a new approach to an old question.
    Goebell PJ; Groshen SG; Schmitz-Dräger BJ;
    Urol Oncol; 2010; 28(4):377-88. PubMed ID: 20610276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cautionary note on the robustness of latent class models for estimating diagnostic error without a gold standard.
    Albert PS; Dodd LE
    Biometrics; 2004 Jun; 60(2):427-35. PubMed ID: 15180668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns.
    Cordon-Cardo C; Dalbagni G; Saez GT; Oliva MR; Zhang ZF; Rosai J; Reuter VE; Pellicer A
    Int J Cancer; 1994 Feb; 56(3):347-53. PubMed ID: 7906253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunohistochemical examination for p53 overexpression in Ta bladder cancer with disease progression].
    Tsukamoto T; Fujioka T; Nakano H; Takanashi K
    Hinyokika Kiyo; 1996 May; 42(5):347-9. PubMed ID: 8752536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of p53 mutations in bladder washings and histologic specimens.
    Vet JA; Hessels D; Marras SA; van de Kaa CA; van der Poel HG; Michalides RJ; Debruyne FM; Schalken JA
    Am J Clin Pathol; 1998 Nov; 110(5):647-52. PubMed ID: 9802351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of MiB1 and p53 expression in human bladder tumors and their correlation with cancer progression.
    Pfister C; Buzelin F; Casse C; Bochereau G; Buzelin JM; Bouchot O
    Eur Urol; 1998; 33(3):278-84. PubMed ID: 9555552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary study of p53 and FGFR3 gene mutations in the urine for bladder tumors].
    Noël N; Couteau J; Maillet G; Gobet F; d'Aloisio F; Minier C; Pfister C
    Prog Urol; 2013 Jan; 23(1):29-35. PubMed ID: 23287481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
    Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma.
    Koyuncuer A
    Indian J Pathol Microbiol; 2013; 56(1):10-5. PubMed ID: 23924551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of nuclear p53 and tumor progression in bladder cancer.
    Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
    N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer.
    Stein JP; Ginsberg DA; Grossfeld GD; Chatterjee SJ; Esrig D; Dickinson MG; Groshen S; Taylor CR; Jones PA; Skinner DG; Cote RJ
    J Natl Cancer Inst; 1998 Jul; 90(14):1072-9. PubMed ID: 9672255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
    Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
    Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study].
    Moreno Sierra J; López García Asenjo JA; Redondo González E; Fernández Pérez C; Maestro de las Casas ML; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
    Arch Esp Urol; 1999 Oct; 52(8):840-8. PubMed ID: 10589115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.